Mathew Bazley

Mathew Bazley has had a diverse range of roles and experiences throughout their career. Starting in 2003, they worked as a Staff Attorney at the U.S. Securities and Exchange Commission until 2006. After that, they joined Skadden, Arps, Slate, Meagher & Flom LLP as a Senior Associate, where they stayed until 2013. In 2013, they transitioned to Savient Pharmaceuticals, Inc., initially serving as Assistant General Counsel and later becoming the Chief Liquidation Officer. In 2014, they joined The Medicines Company as VP, Deputy General Counsel and also took on the role of General Counsel of the Infectious Disease Business Unit. Finally, in 2018, they joined Axovant Gene Therapies, Ltd as the General Counsel.

Mathew Bazley received their Bachelor of Science in Business Administration (BSBA) with a focus on Finance and International Business from Georgetown University in 1994. Mathew later pursued a Juris Doctor and Master of Business Administration (JD/MBA) from Emory University Law and Business Schools, completing their studies in 2003. In 2017, they participated in the Harvard Law School Executive Program, specializing in the Program for General Counsels.